To the best of our knowledge, our study is the first that identified the density of CD134+ cells as a factor predicting the response to treatment with anti-PD-1 agents in metastatic melanoma patients and also showed an association with PFS. This evidence concerns the gene TNFRSF4 and metastatic melanoma.